News Novartis AG Swiss Exchange

Equities

NOVNEE

CH0038459415

Market Closed - Swiss Exchange Other stock markets 11:30:12 2024-05-24 EDT			5-day change	1st Jan Change
91.75 ^CHF	-1.40%		-1.92%	+8.49%

05-25	Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	DJ
05-25	Novartis Presents Results from a Pre-Specified Interim Analysis of the Phase III Align Study	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	05-25	DJ
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	05-25	GL
Novartis Presents Results from a Pre-Specified Interim Analysis of the Phase III Align Study	05-25	CI
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo	05-25	GL
Novartis AG Presents Latest Phase III Fabhalta®? Data in C3 Glomerulopathy	05-25	CI
NOVARTIS AG : Deutsche Bank remains its Buy rating	05-24	ZD
Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating	05-23	MT
NOVARTIS AG : Berenberg remains Neutral	05-23	ZD
Novartis' Cosentyx Receives Canadian Approval for Hidradenitis Suppurativa Treatment	05-23	MT
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	05-22	CF
Amgen And Sandoz Settle Denosumab BPCIA Litigation	05-20	AQ
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15	05-16	DP
Novartis: presents results of tender offer for MorphoSysy	05-16	CF
Novartis Takeover Bid for MorphoSys Tops Minimum Acceptance Threshold	05-16	MT
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash	05-16	GL
Novartis to present results at ASCO and EHA	05-15	CF
Novartis highlights pioneering innovation in CML with data from Scemblix(R) Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA	05-15	DJ
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA	05-15	GL
Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML	05-13	AQ
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales	05-13	DJ